Pricing Log in Create free account
Saturday 17 October 2026 Export ADXN’s income statement to Excel — free account

Addex Therapeutics Ltd. Sponsored ADR

ADXN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.76 0.26 −8.61%
Market cap
$3.2M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
2/9
Altman Z
−78.43
Beneish M
5.79
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3.20
Revenue 0.10
Net Income (8.48)
Free Cash Flow (2.95)
Net Debt (0.97)
Current Ratio 0.76 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.85) (negative: loss-making)
P/S ratio 27.97 (above 10: high)
P/B ratio 1.17
Past 5Y EPS Growth —
This Y EPS Growth 1.26%
Next Y EPS Growth 42.86% (at or above 15%: strong)
Next Y revenue growth 5,145.12% (at or above 10%: strong)
Next 5Y EPS Growth 31.55% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 18.3×, against a ten-year median of 6.3×; over the ten years it ranged from −4.5× in 2022 to 56.4× in 2026.
P/S against its own 10 years 77.73%
10-year low 10-year high
P/B against its own 10 years 37.59%
10-year low 10-year high
EV/Sales against its own 10 years 74.01%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 4 4 2 1
Receivables 0 0 0 0
Inventory — — — —
Other 0 0 0 0
5 4 2 1
2023 2024 2025 Q'26
Payables 3 1 1 2
ST’ Debt — — — —
Other — — — 0
3 1 1 2

Compound Annual Growth %

10y 5y 3y
Sales — (60.68%) (71.04%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (18.07%) 3.77%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — 0 — 0
’24 0 0 0 0 0
’23 1 1 0 0 2
’22 0 0 0 1 1
’21 1 1 1 0 3
’20 1 1 0 2 4
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (1) (1) (3)
’24 (3) (3) (1) 0 (6)
’23 (3) (3) (3) (1) (9)
’22 (5) (105) 97 (3) (17)
’21 (3) (7) (3) (3) (16)
’20 (4) (7) (3) 1 (13)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (1) (1) (3)
’24 (3) (3) (1) 0 (6)
’23 (3) (3) (3) (1) (9)
’22 (5) (105) 97 (3) (17)
’21 (3) (7) (3) (3) (16)
’20 (4) (7) (3) 1 (13)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.21) (2.16) — — —
’25 (2.00) (2.91) (2.10) (2.32) (8.69)
’24 (4.12) 10.61 (2.77) 6.12 9.54
’23 (5.20) (5.00) (0.23) (4.06) (18.70)
’22 (19.40) (23.60) (11.20) (5.00) (57.80)
’21 (10.60) (15.40) (14.40) (16.60) (59.00)
’20 (19.80) (15.00) (15.60) (10.60) (61.40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

4.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 123.80 119.00 11.00 5.00 5.90 6.51

Analyst estimates 2026–2028

Powerpack
High — — — — 750.40 377.40 136.66 45.60 27.90 12.05
People
People Employees — — 17 — 27 28 24 23 2 3
Revenue/emp, $m — 0.00 0.40 0.00 0.14 0.11 0.06 0.08 0.23 0.01
Income, $m
Income, $m Revenue — 1 7 3 4 3 1 2 0 0
Gross margin, % 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (3) (3) (2) 3 (14) (17) (22) (12) (6) (8)
EBT margin, % 0.00 (656.21) (24.54) 100.00 (355.92) (526.42) (1,462.55) (654.46) (1,214.92) (22,814.92)
Net income (3) 0 0 0 (14) (17) (22) (12) 8 (8)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.04 0.29 12.64 17.33 11.22 3.96 2.90 0.56 0.04
Earnings (0.27) (0.26) (0.07) (67.60) (61.40) (59.00) (57.80) (18.70) 9.54 (8.69)
Cash flow (0.23) (0.17) 0.08 (44.86) (58.41) (56.57) (45.75) (14.38) (7.46) (2.93)
Capex 0.00 0.00 0.00 0.00 (0.29) (0.12) 0.00 (0.01) 0.00 0.00
Free cash flow (0.23) (0.17) 0.08 (44.86) (58.70) (56.69) (45.75) (14.39) (7.46) (2.93)
Book value 0.02 0.11 1.72 119.61 70.07 65.13 13.67 2.06 13.44 6.43
Shares, m 11 13 23 0 0 0 0 1 1 1
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.76 0.00
P/S — 0.00 0.00 0.00 15.47 11.21 3.44 2.17 12.47 68.53
P/B — 1.30 1.30 1.30 3.82 1.93 0.99 3.06 0.52 1.20
EV/Sales — 0.00 0.00 0.00 10.29 4.19 (1.46) (0.23) 4.20 48.91
EV/FCF — 0.00 0.00 0.00 (3.04) (0.83) 0.13 0.05 (0.32) (1.88)
Cash, $m
Cash, $m Operating cash flow (3) (2) 2 (10) (13) (16) (17) (9) (6) (3)
Capex 0 0 0 0 0 0 0 0 0 —
Free cash flow (3) (2) 2 (10) (13) (16) (17) (9) (6) (3)
Balance, $m
Balance, $m Working capital 0 2 41 28 17 19 5 1 3 1
Total debt — — — 1 1 1 0 — — —
Net debt (1) (3) (43) (33) (20) (22) (7) (4) (4) (2)
Shareholders’ equity 0 1 40 26 16 19 5 1 11 6
Returns, %
Returns, % ROA (129.31) (405.76) 0.00 0.00 (118.36) (72.73) (130.77) (169.81) 92.65 (81.98)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (27.18) (56.24)
ROE (389.80) (422.59) (8.11) (44.84) (65.47) (98.49) (184.19) (366.08) 130.66 (96.99)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 30 Sep 2026

Charts ten years each

Addex Therapeutics Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PBLA Panbela Therapeutics Inc. $3.4M — (loss-making) — — n/m +66.23% (above 0%: growing) — 0.00% Compare
CMND Clearmind Medicine Inc. $3.3M — (loss-making) — — n/m −77.94% (below 0%: shrinking) 0.00% 0.00% Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR $3.2M — (loss-making) — (loss-making) −100.78% (below 0%: shrinking) n/m −2.73% (below 0%: shrinking) 100.00% 0.00%
CLDI Calidi Biotherapeutics, Inc. $3.2M — (loss-making) — — n/m +11.16% (above 0%: growing) — 0.00% Compare
EOCN Eocene Ltd. $3.2M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −67.74% (below 0%: shrinking) 0.00% 0.00% Compare
SXTP 60 Degrees Pharmaceuticals Inc. $3.2M — (loss-making) — (loss-making) −32.48% (below 0%: shrinking) n/m −54.33% (below 0%: shrinking) 27.32% (1,092.40%) Compare
APVO Aptevo Therapeutics Inc. $3.1M 0.0× — (loss-making) +28.62% (above 0%: growing) n/m +23.11% (above 0%: growing) 0.00% 0.00% Compare
GRI GRI Bio, Inc. $3.1M 0.0× — (loss-making) — n/m +54.33% (above 0%: growing) 0.00% 0.00% Compare
REVB Revelation Biosciences, Inc. $3.0M — (loss-making) — — n/m −35.29% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $3.2M — — −32.48% — −12.06% 0.00% 0.00%

All 614 Biotechnology stocks →

Addex Therapeutics Ltd. Sponsored ADR (ADXN) key facts

  • Addex Therapeutics Ltd. Sponsored ADR (ADXN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ADXN traded at $2.76, a market capitalization of $3.2 million.
  • Return on equity was −97.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −78.43 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 30, 2026.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ADXN · Data as of Sep 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com